Reaction
Myocardial Necrosis Marker Increased reporting signals
As of the last recalculation, Myocardial Necrosis Marker Increased appears in 1,602 FAERS reports alongside 23 co-occurring drug terms. The strongest observed disproportionality signal is AGALSIDASE BETA (PRR 25.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Agalsidase Beta | 18 | 25.6 | 25.6 |
| Crizotinib | 21 | 21.7 | 21.8 |
| Durvalumab | 21 | 13.6 | 13.6 |
| Atropine | 8 | 12.6 | 12.6 |
| Atropine Sulfate | 9 | 10.9 | 10.9 |
| Ticagrelor | 26 | 10.7 | 10.8 |
| Carfilzomib | 21 | 9.8 | 9.8 |
| Selexipag | 19 | 9.7 | 9.7 |
| Atorvastatin Calcium | 157 | 9.0 | 9.0 |
| Acalabrutinib | 6 | 6.5 | 6.5 |
| Sevoflurane | 4 | 6.3 | 6.3 |
| Atezolizumab | 18 | 6.1 | 6.1 |
| Riociguat | 14 | 5.6 | 5.6 |
| Axitinib | 8 | 5.4 | 5.4 |
| Osimertinib | 13 | 5.3 | 5.3 |
| Pembrolizumab | 36 | 4.5 | 4.5 |
| Avapritinib | 4 | 4.3 | 4.3 |
| Sofosbuvir | 6 | 4.0 | 4.0 |
| Treprostinil | 36 | 3.8 | 3.8 |
| Droxidopa | 6 | 3.6 | 3.6 |
| Apalutamide | 3 | 3.3 | 3.3 |
| Sacubitril And Valsartan | 29 | 3.3 | 3.3 |
| Pimavanserin Tartrate | 7 | 1.6 | 1.6 |